PG 11047

Drug Profile

PG 11047

Alternative Names: CGC-11047; PG-11047; SL-11047

Latest Information Update: 13 Mar 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cellgate
  • Developer EPI Pharmaceuticals; Progen Pharmaceuticals Inc
  • Class Antineoplastics; Polyamines
  • Mechanism of Action Apoptosis stimulants; Cell division modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours
  • Discontinued Age-related macular degeneration; Prostate cancer

Most Recent Events

  • 24 Feb 2012 Progen completes the phase Ib 47-01-002 trial for Solid tumours and lymphoma in the USA (NCT00705874)
  • 14 Dec 2011 Progen Pharmaceuticals completes EPI Pharmaceuticals formation and transfers the epigenetic and cell proliferation assets to EPI
  • 06 Apr 2011 Progen completes enrolment in the phase Ib 47-01-002 trial for Solid tumours & lymphoma in USA (NCT00705874)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top